1
|
PTEN: An Emerging Potential Target for Therapeutic Intervention in Respiratory Diseases. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2022; 2022:4512503. [PMID: 35814272 PMCID: PMC9262564 DOI: 10.1155/2022/4512503] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/06/2021] [Revised: 04/22/2022] [Accepted: 05/19/2022] [Indexed: 12/13/2022]
Abstract
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a potent tumor suppressor that regulates several key cellular processes, including proliferation, survival, genomic integrity, migration, and invasion, via PI3K-dependent and independent mechanisms. A subtle decrease in PTEN levels or catalytic activity is implicated not only in cancer but also in a wide spectrum of other diseases, including various respiratory diseases. A systemic overview of the advances in the molecular and cellular mechanisms of PTEN involved in the initiation and progression of respiratory diseases may offer novel targets for the development of effective therapeutics for the treatment of respiratory diseases. In the present review, we highlight the novel findings emerging from current research on the role of PTEN expression and regulation in airway pathological conditions such as asthma/allergic airway inflammation, pulmonary hypertension (PAH), chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and other acute lung injuries (ALI). Moreover, we discuss the clinical implications of PTEN alteration and recently suggested therapeutic possibilities for restoration of PTEN expression and function in respiratory diseases.
Collapse
|
2
|
Wang E, Tu W, Do DC, Xiao X, Bhatti SB, Yang L, Sun X, Xu D, Yang P, Huang SK, Gao P, Liu Z. Benzo(a)pyrene Enhanced Dermatophagoides Group 1 (Der f 1)-Induced TGFβ1 Signaling Activation Through the Aryl Hydrocarbon Receptor-RhoA Axis in Asthma. Front Immunol 2021; 12:643260. [PMID: 33936062 PMCID: PMC8081905 DOI: 10.3389/fimmu.2021.643260] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Accepted: 02/24/2021] [Indexed: 12/18/2022] Open
Abstract
We have previously demonstrated that benzo(a)pyrene (BaP) co-exposure with dermatophagoides group 1 allergen (Der f 1) can potentiate Der f 1-induced airway inflammation. The underlying mechanism, however, remains undetermined. Here we investigated the molecular mechanisms underlying the potentiation of BaP exposure on Der f 1-induced airway inflammation in asthma. We found that BaP co-exposure potentiated Der f 1-induced TGFβ1 secretion and signaling activation in human bronchial epithelial cells (HBECs) and the airways of asthma mouse model. Moreover, BaP exposure alone or co-exposure with Der f 1-induced aryl hydrocarbon receptor (AhR) activity was determined by using an AhR-dioxin-responsive element reporter plasmid. The BaP and Der f 1 co-exposure-induced TGFβ1 expression and signaling activation were attenuated by either AhR antagonist CH223191 or AhR knockdown in HBECs. Furthermore, AhR knockdown led to the reduction of BaP and Der f 1 co-exposure-induced active RhoA. Inhibition of RhoA signaling with fasudil, a RhoA/ROCK inhibitor, suppressed BaP and Der f 1 co-exposure-induced TGFβ1 expression and signaling activation. This was further confirmed in HBECs expressing constitutively active RhoA (RhoA-L63) or dominant-negative RhoA (RhoA-N19). Luciferase reporter assays showed prominently increased promoter activities for the AhR binding sites in the promoter region of RhoA. Inhibition of RhoA suppressed BaP and Der f 1 co-exposure-induced airway hyper-responsiveness, Th2-associated airway inflammation, and TGFβ1 signaling activation in asthma. Our studies reveal a previously unidentified functional axis of AhR–RhoA in regulating TGFβ1 expression and signaling activation, representing a potential therapeutic target for allergic asthma.
Collapse
Affiliation(s)
- Eryi Wang
- Department of Respiratory and Allergy, Third Affiliated Hospital of Shenzhen University, Shenzhen, China.,The State Key Laboratory of Respiratory Disease for Allergy, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China
| | - Wei Tu
- Department of Respiratory and Allergy, Third Affiliated Hospital of Shenzhen University, Shenzhen, China.,The State Key Laboratory of Respiratory Disease for Allergy, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China.,Johns Hopkins Asthma and Allergy Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States
| | - Danh C Do
- Johns Hopkins Asthma and Allergy Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States
| | - Xiaojun Xiao
- The State Key Laboratory of Respiratory Disease for Allergy, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China
| | - Shehar B Bhatti
- Johns Hopkins Asthma and Allergy Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States
| | - Liteng Yang
- Department of Respiratory and Allergy, Third Affiliated Hospital of Shenzhen University, Shenzhen, China
| | - Xizhuo Sun
- Department of Respiratory and Allergy, Third Affiliated Hospital of Shenzhen University, Shenzhen, China
| | - Damo Xu
- Department of Respiratory and Allergy, Third Affiliated Hospital of Shenzhen University, Shenzhen, China.,The State Key Laboratory of Respiratory Disease for Allergy, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China
| | - Pingchang Yang
- Department of Respiratory and Allergy, Third Affiliated Hospital of Shenzhen University, Shenzhen, China.,The State Key Laboratory of Respiratory Disease for Allergy, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China
| | - Shau-Ku Huang
- Department of Respiratory and Allergy, Third Affiliated Hospital of Shenzhen University, Shenzhen, China.,Johns Hopkins Asthma and Allergy Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States.,National Institute of Environmental Health Sciences, National Health Research Institutes, Miaoli, Taiwan
| | - Peisong Gao
- Johns Hopkins Asthma and Allergy Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States
| | - Zhigang Liu
- Department of Respiratory and Allergy, Third Affiliated Hospital of Shenzhen University, Shenzhen, China.,The State Key Laboratory of Respiratory Disease for Allergy, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China
| |
Collapse
|
3
|
Chen L, Shi L, Ma Y, Zheng C. Hub Genes Identification in a Murine Model of Allergic Rhinitis Based on Bioinformatics Analysis. Front Genet 2020; 11:970. [PMID: 33193578 PMCID: PMC7477359 DOI: 10.3389/fgene.2020.00970] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Accepted: 07/31/2020] [Indexed: 12/16/2022] Open
Abstract
This study aimed to identify allergic rhinitis (AR)-related hub genes and functionally enriched pathways in a murine model. Dataset GSE52804 (including three normal controls and three AR mice) was downloaded from Gene Expression Omnibus (GEO). Differentially expressed genes (DEGs) were identified. Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, and protein-protein interaction (PPI) analyses of DEGs were performed to identify the hub genes in AR. The DEGs were classified into different modules by using the weighted gene co-expression network analysis (WGCNA). Moreover, to verify the potential hub genes, nasal mucosa tissues were obtained from murine AR models (n = 5) and controls (n = 5), and qRT-PCR and Western blot were performed. In this study, a total of 634 DEGs were identified. They were significantly enriched in 14 GO terms, such as integral component of membrane, plasma membrane, and G-protein-coupled receptor signaling pathway. Meanwhile, there were eight terms of KEGG pathways significantly enriched, such as Olfactory transduction, Cytokine-cytokine receptor interaction, and TNF signaling pathway. The top 10 hub genes (Rtp1, Rps27a, Penk, Cxcl2, Gng8, Gng3, Cxcl1, Cxcr2, Ccl9, and Anxa1) were identified by the PPI network. DEGs were classified into seven modules by WGCNA. According to qRT-PCR validation of the five genes of interest (Rtp1, Rps27a, Penk, Cxcl2, and Anxa1), the expression level of Rtp1 mRNA was significantly decreased in the AR group compared with the control group, while there are enhanced Rps27a, Penk, Cxcl2, and Anxa1 mRNA expressions in the AR mice group compared with the control group. Western blot was also performed to further explore the expression of Anxa1 in the protein level, and the results showed a similar expression trend.
Collapse
Affiliation(s)
- Le Chen
- Department of Otolaryngology-Head and Neck Surgery, Eye, Ear, Nose, and Throat Hospital, Fudan University, Shanghai, China.,Shanghai Key Clinical Disciplines of Otorhinolaryngology, Shanghai, China
| | - Le Shi
- Department of Otolaryngology-Head and Neck Surgery, Eye, Ear, Nose, and Throat Hospital, Fudan University, Shanghai, China.,Shanghai Key Clinical Disciplines of Otorhinolaryngology, Shanghai, China
| | - Yue Ma
- Department of Otolaryngology-Head and Neck Surgery, Eye, Ear, Nose, and Throat Hospital, Fudan University, Shanghai, China.,Shanghai Key Clinical Disciplines of Otorhinolaryngology, Shanghai, China
| | - Chunquan Zheng
- Department of Otolaryngology-Head and Neck Surgery, Eye, Ear, Nose, and Throat Hospital, Fudan University, Shanghai, China
| |
Collapse
|
4
|
Wang E, Liu X, Tu W, Do DC, Yu H, Yang L, Zhou Y, Xu D, Huang S, Yang P, Ran P, Gao P, Liu Z. Benzo(a)pyrene facilitates dermatophagoides group 1 (Der f 1)-induced epithelial cytokine release through aryl hydrocarbon receptor in asthma. Allergy 2019; 74:1675-1690. [PMID: 30982974 PMCID: PMC6790621 DOI: 10.1111/all.13784] [Citation(s) in RCA: 56] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2018] [Revised: 01/24/2019] [Accepted: 02/18/2019] [Indexed: 01/12/2023]
Abstract
BACKGROUND Environmental pollutants, which coexist with allergens, have been associated with the exacerbation of asthma. However, the underlying molecular mechanisms remain elusive. We sought to determine whether benzo(a)pyrene (BaP) co-exposure with dermatophagoides group 1 allergen (Der f 1) can potentiate Der f 1-induced asthma and its underlying mechanisms. METHODS The effect of BaP was investigated in Der f 1-induced mouse model of asthma, including airway hyper-responsiveness, allergic inflammation, and epithelial-derived cytokines. The impact of BaP on Der f 1-induced airway epithelial cell oxidative stress (ROS) and cytokine release was further analyzed. The role of aryl hydrocarbon receptor (AhR) signaling in BaP-promoted Der f 1-induced ROS, cytokine production, and allergic inflammation was also investigated. RESULTS Compared with Der f 1, BaP co-exposure with Der f 1 led to airway hyper-responsiveness and increased lung inflammation in mouse model of asthma. Increased expression of TSLP, IL-33, and IL-25 was also found in the airways of these mice. Moreover, BaP co-exposure with Der f 1 activated AhR signaling with increased expression of AhR and CYP1A1 and promoted airway epithelial ROS generation and TSLP and IL-33, but not IL-25, expression. Interestingly, AhR antagonist CH223191 or cells with AhR knockdown abrogated the increased expression of ROS, TSLP, and IL-33. Furthermore, ROS inhibitor N-acetyl-L-cysteine (NAC) also suppressed BaP co-exposure-induced expression of epithelial TSLP, IL-33, and IL-25. Finally, AhR antagonist CH223191 and NAC inhibited BaP co-exposure with Der f 1-induced lung inflammation. CONCLUSIONS Our findings suggest that BaP facilitates Der f 1-induced epithelial cytokine release through the AhR-ROS axis.
Collapse
Affiliation(s)
- Eryi Wang
- The Affiliated Luohu Hospital of Shenzhen University, Shenzhen Luohu Hospital GroupShenzhenChina
- The State Key Laboratory of Respiratory Disease for Allergy, Shenzhen University School of MedicineShenzhen UniversityShenzhenChina
| | - Xiaoyu Liu
- The State Key Laboratory of Respiratory Disease for Allergy, Shenzhen University School of MedicineShenzhen UniversityShenzhenChina
| | - Wei Tu
- The Affiliated Luohu Hospital of Shenzhen University, Shenzhen Luohu Hospital GroupShenzhenChina
- The State Key Laboratory of Respiratory Disease for Allergy, Shenzhen University School of MedicineShenzhen UniversityShenzhenChina
| | - Danh C. Do
- Johns Hopkins Asthma and Allergy CenterJohns Hopkins University School of MedicineBaltimoreMaryland
| | - Haiqiong Yu
- The Affiliated Luohu Hospital of Shenzhen University, Shenzhen Luohu Hospital GroupShenzhenChina
| | - Liteng Yang
- The Affiliated Luohu Hospital of Shenzhen University, Shenzhen Luohu Hospital GroupShenzhenChina
| | - Yufeng Zhou
- Key Laboratory of Neonatal Disease, Ministry of Health, Children's Hospital and Institute of Biomedical SciencesFudan UniversityShanghaiChina
| | - Damo Xu
- Institute of Infection, Immunity and InflammationUniversity of GlasgowGlasgowUK
| | - Shau‐Ku Huang
- The Affiliated Luohu Hospital of Shenzhen University, Shenzhen Luohu Hospital GroupShenzhenChina
- Johns Hopkins Asthma and Allergy CenterJohns Hopkins University School of MedicineBaltimoreMaryland
- National Institute of Environmental Health SciencesNational Health Research InstitutesMiaoliTaiwan
| | - Pingchang Yang
- The Affiliated Luohu Hospital of Shenzhen University, Shenzhen Luohu Hospital GroupShenzhenChina
- The State Key Laboratory of Respiratory Disease for Allergy, Shenzhen University School of MedicineShenzhen UniversityShenzhenChina
| | - Pixin Ran
- Guangzhou Institute of Respiratory Disease, State Key Laboratory of Respiratory Diseases, The First Affiliated HospitalGuangzhou Medical UniversityGuangzhouChina
| | - Pei‐Song Gao
- Johns Hopkins Asthma and Allergy CenterJohns Hopkins University School of MedicineBaltimoreMaryland
| | - Zhigang Liu
- The Affiliated Luohu Hospital of Shenzhen University, Shenzhen Luohu Hospital GroupShenzhenChina
- The State Key Laboratory of Respiratory Disease for Allergy, Shenzhen University School of MedicineShenzhen UniversityShenzhenChina
| |
Collapse
|
5
|
Liu QH, Yong HM, Zhuang QX, Zhang XP, Hou PF, Chen YS, Zhu MH, Bai J. Reduced expression of annexin A1 promotes gemcitabine and 5-fluorouracil drug resistance of human pancreatic cancer. Invest New Drugs 2019; 38:350-359. [PMID: 31124054 DOI: 10.1007/s10637-019-00785-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2019] [Accepted: 04/18/2019] [Indexed: 12/24/2022]
Abstract
Intrinsic chemoresistance is the main reason for the failure of human pancreatic ductal adenocarcinoma (PDAC) therapy. To identify the candidate protein, we compared the protein expression profiling of PDAC cells and its distinct surviving cells following primary treatment with gemcitabine (GEM) and 5-fluorouracil (5-FU) by two-dimensional electrophoresis combined with liquid chromatography-mass spectrometry or mass spectrometry. A total of 20 differentially expressed proteins were identified, and annexin A1 (ANXA1) was analyzed for further validation. The functional validation showed that the downregulation of ANXA1 contributes to GEM and 5-FU resistance in PDAC cells through protein kinase C/c-Jun N-terminal kinase/P-glycoprotein signaling pathway. Our findings provide a platform for the further elucidation of the underlying mechanisms of PDAC intrinsic chemoresistance and demonstrated that ANXA1 may be a valid marker for anticancer drug development.
Collapse
Affiliation(s)
- Qing-Hua Liu
- Cancer Institute, Xuzhou Medical University, 84 West Huaihai Road, Xuzhou, 221002, Jiangsu Province, China.,Department of Pathology, Xuzhou Medical University, Xuzhou, Jiangsu Province, China
| | - Hong-Mei Yong
- Department of Medical Oncology, Huai'an Hospital to Xuzhou Medical University, Huai'an, Jiangsu Province, China
| | - Qing-Xin Zhuang
- Department of Medical Oncology, People's Hospital of Ningxia Hui Autonomous Region/The First Affiliated Hospital of Northwest University of Nationalities, Yinchuan, Ningxia Hui Autonomous Region, China
| | - Xu-Ping Zhang
- Cancer Institute, Xuzhou Medical University, 84 West Huaihai Road, Xuzhou, 221002, Jiangsu Province, China
| | - Ping-Fu Hou
- Cancer Institute, Xuzhou Medical University, 84 West Huaihai Road, Xuzhou, 221002, Jiangsu Province, China.,Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu Province, China
| | - Yan-Su Chen
- Cancer Institute, Xuzhou Medical University, 84 West Huaihai Road, Xuzhou, 221002, Jiangsu Province, China.,Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu Province, China
| | - Ming-Hua Zhu
- Department of Pathology, Changhai Hospital, Secondary Military Medical University, 168 Changhai Road, Shanghai, 200433, China.
| | - Jin Bai
- Cancer Institute, Xuzhou Medical University, 84 West Huaihai Road, Xuzhou, 221002, Jiangsu Province, China. .,Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu Province, China.
| |
Collapse
|